These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 29566909)

  • 21. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
    Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
    Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics.
    He X; Ji G; Jia W; Li H
    Int J Mol Sci; 2016 Mar; 17(3):300. PubMed ID: 26999104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characteristics of intestinal bacteria with fatty liver diseases and cirrhosis.
    Guohong-Liu ; Qingxi-Zhao ; Hongyun-Wei
    Ann Hepatol; 2019; 18(6):796-803. PubMed ID: 31558417
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.
    Cho MS; Kim SY; Suk KT; Kim BY
    J Microbiol; 2018 Dec; 56(12):855-867. PubMed ID: 30377993
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Suppressed hepatic bile acid signalling despite elevated production of primary and secondary bile acids in NAFLD.
    Jiao N; Baker SS; Chapa-Rodriguez A; Liu W; Nugent CA; Tsompana M; Mastrandrea L; Buck MJ; Baker RD; Genco RJ; Zhu R; Zhu L
    Gut; 2018 Oct; 67(10):1881-1891. PubMed ID: 28774887
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites.
    Ding Y; Yanagi K; Cheng C; Alaniz RC; Lee K; Jayaraman A
    Pharmacol Res; 2019 Mar; 141():521-529. PubMed ID: 30660825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease.
    Wieland A; Frank DN; Harnke B; Bambha K
    Aliment Pharmacol Ther; 2015 Nov; 42(9):1051-63. PubMed ID: 26304302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders.
    Aron-Wisnewsky J; Vigliotti C; Witjes J; Le P; Holleboom AG; Verheij J; Nieuwdorp M; Clément K
    Nat Rev Gastroenterol Hepatol; 2020 May; 17(5):279-297. PubMed ID: 32152478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gut Microbiota: Association with NAFLD and Metabolic Disturbances.
    Lau E; Carvalho D; Freitas P
    Biomed Res Int; 2015; 2015():979515. PubMed ID: 26090468
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Gut Microbiota and Its Metabolites, Novel Targets for Treating and Preventing Non-Alcoholic Fatty Liver Disease.
    Ni Y; Ni L; Zhuge F; Fu Z
    Mol Nutr Food Res; 2020 Sep; 64(17):e2000375. PubMed ID: 32738185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diet-Independent Correlations between Bacteria and Dysfunction of Gut, Adipose Tissue, and Liver: A Comprehensive Microbiota Analysis in Feces and Mucosa of the Ileum and Colon in Obese Mice with NAFLD.
    Gart E; Souto Lima E; Schuren F; de Ruiter CGF; Attema J; Verschuren L; Keijer J; Salic K; Morrison MC; Kleemann R
    Int J Mol Sci; 2018 Dec; 20(1):. PubMed ID: 30577415
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease.
    Shen F; Zheng RD; Sun XQ; Ding WJ; Wang XY; Fan JG
    Hepatobiliary Pancreat Dis Int; 2017 Aug; 16(4):375-381. PubMed ID: 28823367
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A cohort study on Helicobacter pylori infection associated with nonalcoholic fatty liver disease.
    Kim TJ; Sinn DH; Min YW; Son HJ; Kim JJ; Chang Y; Baek SY; Ahn SH; Lee H; Ryu S
    J Gastroenterol; 2017 Nov; 52(11):1201-1210. PubMed ID: 28382402
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Obesity, fatty liver disease and intestinal microbiota.
    Arslan N
    World J Gastroenterol; 2014 Nov; 20(44):16452-63. PubMed ID: 25469013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-alcoholic fatty liver disease: An update with special focus on the role of gut microbiota.
    Doulberis M; Kotronis G; Gialamprinou D; Kountouras J; Katsinelos P
    Metabolism; 2017 Jun; 71():182-197. PubMed ID: 28521872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gut Microbiota as a Driver of Inflammation in Nonalcoholic Fatty Liver Disease.
    Bibbò S; Ianiro G; Dore MP; Simonelli C; Newton EE; Cammarota G
    Mediators Inflamm; 2018; 2018():9321643. PubMed ID: 29563854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD).
    Ji Y; Yin Y; Li Z; Zhang W
    Nutrients; 2019 Jul; 11(8):. PubMed ID: 31349604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of shenling baizhu powder herbal formula on intestinal microbiota in high-fat diet-induced NAFLD rats.
    Zhang Y; Tang K; Deng Y; Chen R; Liang S; Xie H; He Y; Chen Y; Yang Q
    Biomed Pharmacother; 2018 Jun; 102():1025-1036. PubMed ID: 29710519
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between Helicobacter pylori infection and risk of nonalcoholic fatty liver disease: An updated meta-analysis.
    Mantovani A; Turino T; Altomari A; Lonardo A; Zoppini G; Valenti L; Tilg H; Byrne CD; Targher G
    Metabolism; 2019 Jul; 96():56-65. PubMed ID: 31047909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.